A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Enzastaurin (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Biomarker; Therapeutic Use
- Acronyms ENGINE
- Sponsors Denovo Biopharma
- 12 Jan 2018 Planned End Date changed from 1 May 2021 to 1 Sep 2021.
- 12 Jan 2018 Planned primary completion date changed from 1 Jun 2020 to 1 Oct 2020.
- 12 Jan 2018 Planned initiation date changed from 1 Oct 2017 to 1 Mar 2018.